US 12,226,417 B2
Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
Joseph K. Belanoff, Menlo Park, CA (US); Hazel Hunt, Storrington (GB); Onno C. Meijer, Leiden (NL); and José van den Heuvel, Leiden (NL)
Assigned to Corcept Therapeutics, Inc., Redwood City, CA (US)
Filed by Corcept Therapeutics, Inc., Menlo Park, CA (US)
Filed on Jan. 26, 2023, as Appl. No. 18/101,986.
Application 18/101,986 is a continuation of application No. 17/111,288, filed on Dec. 3, 2020, granted, now 11,590,135.
Application 17/111,288 is a continuation of application No. 16/256,295, filed on Jan. 24, 2019, granted, now 10,881,660, issued on Jan. 5, 2021.
Application 16/256,295 is a continuation of application No. 14/883,369, filed on Oct. 14, 2015, granted, now 10,238,659, issued on Mar. 26, 2019.
Claims priority of provisional application 62/092,041, filed on Dec. 15, 2014.
Claims priority of provisional application 62/064,358, filed on Oct. 15, 2014.
Prior Publication US 2023/0218621 A1, Jul. 13, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/513 (2006.01); A61P 1/16 (2006.01)
CPC A61K 31/513 (2013.01) [A61P 1/16 (2018.01)] 20 Claims
 
1. A method of treating fatty liver disease, comprising: administering to a subject in need thereof, a therapeutically effective amount of between 10 milligrams (mg) and 500 mg of a compound of Formula Id,
wherein said administering comprises oral administration of said compound of Formula Id, wherein the compound of Formula Id has the structure:

OG Complex Work Unit Chemistry
wherein
each R1a is independently H, C1-6 alkyl, halogen, or C1-6 haloalkyl;
R2 is H, or C1-6 alkyl; and
each R4 is H, C1-6 alkyl, halogen, or C1-6 haloalkyl;
or salts or isomers thereof.